1802735-28-9
Chemical Structure
QBS10072S
- CAS No.: 1802735-28-9
- Formula:C15H22Cl2N2O2
- Molecular Weight:333.25
InChIKey: CWYYHMPCMCTGFA-ZDUSSCGKSA-N
SMILES: CC1=C(C[C@@H](CC(O)=O)N)C=C(N(CCCl)CCCl)C=C1
Biological Activity: QBS10072S is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
QBS10072S | QBS10072S is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nicolaides TP, et al. Abstract B125: A novel BBB-permeable chemotherapeutic agent for the treatment of CNS tumors. Mol Cancer Ther. 2018 Jan 01;17(1_Supplement):B125.
- [2]. Deng J, et al. A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer. Mol Cancer Ther. 2021;20(11):2110-2116. [Content Brief]
- [3]. Murga-Zamalloa C, et al. Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. Leuk Res Rep. 2023;21:100398. Published 2023 Nov 22. [Content Brief]
